These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21059813)

  • 1. Pazopanib in renal cell carcinoma.
    Ward JE; Stadler WM
    Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
    Sonpavde G; Hutson TE; Sternberg CN
    Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
    Bukowski RM
    Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
    Koc G; Wang X; Luo Y
    Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib: therapeutic developments.
    Limvorasak S; Posadas EM
    Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
    Prescrire Int; 2011 Mar; 20(114):64-6. PubMed ID: 21648224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
    Bourdeanu L; Twardowski P; Pal SK
    Clin J Oncol Nurs; 2011 Oct; 15(5):513-7. PubMed ID: 21951737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
    LaPlant KD; Louzon PD
    Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Borregaard J; Ersbøll J; ten Bosch GJ; van Zwieten-Boot B; Abadie E; Schellens JH; Pignatti F
    Clin Cancer Res; 2011 Nov; 17(21):6608-14. PubMed ID: 21976546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
    Kasper B; Hohenberger P
    Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.
    Cella D; Pickard AS; Duh MS; Guerin A; Mishagina N; Antràs L; Neary MP; McCann L; Hodge R; Sternberg CN
    Eur J Cancer; 2012 Feb; 48(3):311-23. PubMed ID: 21689927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
    Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.
    Melichar B; Studentová H; Zezulová M
    J BUON; 2011; 16(2):203-9. PubMed ID: 21766486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
    Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
    Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].
    Rexer H
    Urologe A; 2011 Apr; 50(4):489-92. PubMed ID: 21472622
    [No Abstract]   [Full Text] [Related]  

  • 20. Pazopanib in renal cell carcinoma.
    Sternberg CN
    Clin Adv Hematol Oncol; 2010 Apr; 8(4):232-3. PubMed ID: 20505644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.